Hims & Hers Health (NYSE:HIMS) CFO Sells $619,243.91 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 18,197 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $34.03, for a total value of $619,243.91. Following the completion of the sale, the chief financial officer owned 284,321 shares in the company, valued at $9,675,443.63. The trade was a 6.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, May 18th, Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.64, for a total value of $187,938.00.
• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.96, for a total value of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.90, for a total value of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.83, for a total value of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.98, for a total value of $79,420.50.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $32.77 on Friday. The business has a fifty day moving average price of $27.75 and a 200-day moving average price of $26.41. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The company has a market capitalization of $7.59 billion, a PE ratio of -364.17, a PEG ratio of 46.74 and a beta of 2.37. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the previous year, the firm earned $0.20 EPS. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.05 EPS for the current fiscal year.

Analyst Ratings Changes

HIMS has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a report on Friday, May 22nd. TD Cowen lowered their price objective on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, March 27th. Zacks Research downgraded Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research note on Monday, June 8th. Finally, Canaccord Genuity Group set a $32.00 target price on Hims & Hers Health in a report on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $29.37.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently made changes to their positions in the stock. Sigma Planning Corp grew its stake in shares of Hims & Hers Health by 1.5% during the 1st quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock valued at $540,000 after purchasing an additional 388 shares during the period. BAM Wealth Management LLC lifted its stake in shares of Hims & Hers Health by 5.6% in the 4th quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock worth $240,000 after purchasing an additional 393 shares during the period. Xponance Inc. boosted its holdings in shares of Hims & Hers Health by 1.5% in the third quarter. Xponance Inc. now owns 28,195 shares of the company’s stock worth $1,599,000 after buying an additional 419 shares during the last quarter. Captrust Financial Advisors grew its position in Hims & Hers Health by 3.1% during the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock valued at $728,000 after buying an additional 443 shares during the period. Finally, Sherman Porfolios LLC grew its position in Hims & Hers Health by 10.5% during the third quarter. Sherman Porfolios LLC now owns 4,934 shares of the company’s stock valued at $280,000 after buying an additional 467 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.